SCHWAZZE SIGNS DEFINITIVE DOCUMENTS TO ACQUIRE TWO RETAIL DISPENSARIES FROM SMOKEY'S CANNABIS COMPANY

Rhea-AI Summary

Schwazze (NEO: SHWZ) has announced the acquisition of Smokey's dispensaries in Fort Collins and Garden City, Colorado, for US$7.5 million, split into $3.75 million cash and $3.75 million stock. This acquisition will expand Schwazze's footprint to 27 dispensaries in Colorado, enhancing its market presence in limited-license areas. The deal is set to close by Q2 2023, pending regulatory approvals. President Nirup Krishnamurthy expressed optimism about serving new customers and deepening operations in northern Colorado. Since April 2020, Schwazze has acquired or opened a total of 44 dispensaries across Colorado and New Mexico.

Positive

• Strategic acquisition of two dispensaries enhances market presence in northern Colorado.
• Total dispensary count will rise to 27, reflecting aggressive growth strategy.
• Acquisition value of US$7.5 million suggests confidence in future revenue generation.

Negative

• Acquisition is subject to regulatory approvals, which could delay expansion plans.
• Financing structure includes stock, raising potential dilution concerns.

Argus Session date unavailable

+0.71% session move Open Argus

Details

News Market Reaction – SHWZ

The recorded move for SHWZ in the trading session of this news was +0.71%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEO: SHWZ
OTCQX: SHWZ

Star Buds Retailer Now Enters the Fort Collins and Garden City Markets in Colorado

DENVER, Feb. 21, 2023 /PRNewswire/ - Schwazze, (NEO: SHWZ) (OTCQX: SHWZ) ("Schwazze" or the "Company"), announced that it has signed definitive documents to acquire certain assets of Cannabis Care Wellness Centers, LLC and Green Medicals Wellness Center #5, LLC (d/b/a "Smokey's").  The proposed transaction includes the adult use Smokey's dispensaries located at 2515 7^th Avenue in Garden City as well as 5740 S. College Ave. in Fort Collins. These two vibrant cannabis markets have limited licenses and present Schwazze with more opportunities to serve customers in northern Colorado. This acquisition continues Schwazze's deliberate expansion in Colorado and, upon close, will bring the Company's total number of Colorado dispensaries to 27.

The consideration for the proposed acquisition is US$7.5 million and will be paid as $3.75M cash and $3.75M stock at closing. The acquisition is expected to close in the second quarter of 2023 after Colorado Marijuana Enforcement Division and local licensing approvals.

"We are excited to bring our Star Buds operations to Garden City and Fort Collins. Bringing our operating playbook to two key cities in northern Colorado allows us to deliver our brands, product assortment and our dedicated service to customers in new neighborhoods as we continue to go deep in the state," said Nirup Krishnamurthy, President of Schwazze.    

Since April 2020, Schwazze has acquired, announced the planned acquisition of, or opened 44 cannabis dispensaries as well as seven cultivation facilities and two manufacturing assets in Colorado and New Mexico. In May 2021, Schwazze announced its BioSciences division and in August 2021 it commenced home delivery services in Colorado.

About Schwazze

Schwazze (NEO: SHWZ) (OTCQX: SHWZ) is building a premier vertically integrated regional cannabis company with assets in Colorado and New Mexico and will continue to take its operating system to other states where it can develop a differentiated regional leadership position. Schwazze is the parent company of a portfolio of leading cannabis businesses and brands spanning seed to sale. The Company is committed to unlocking the full potential of the cannabis plant to improve the human condition. Schwazze is anchored by a high-performance culture that combines customer-centric thinking and data science to test, measure, and drive decisions and outcomes. The Company's leadership team has deep expertise in retailing, wholesaling, and building consumer brands at Fortune 500 companies as well as in the cannabis sector. Schwazze is passionate about making a difference in our communities, promoting diversity and inclusion, and doing our part to incorporate climate-conscious best practices.

Medicine Man Technologies, Inc. was Schwazze's former operating trade name. The corporate entity continues to be named Medicine Man Technologies, Inc. Schwazze derives its name from the pruning technique of a cannabis plant to enhance plant structure and promote healthy growth.

Forward-Looking Statements

This press release contains "forward-looking statements." Such statements may be preceded by the words "plan," "will," "may," "continue," "predicts," or similar words. Forward-looking statements are not guarantees of future events or performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control and cannot be predicted or quantified. Consequently, actual events and results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) our inability to manufacture our products and product candidates on a commercial scale on our own or in collaboration with third parties; (ii) difficulties in obtaining financing on commercially reasonable terms; (iii) changes in the size and nature of our competition; (iv) loss of one or more key executives or scientists; (v) difficulties in securing regulatory approval to market our products and product candidates; (vi) our ability to successfully execute our growth strategy in Colorado and outside the state, (vii) our ability to consummate the acquisition described in this press release or to identify and consummate future acquisitions that meet our criteria, (viii) our ability to successfully integrate acquired businesses, including the acquisition described in this press release, and realize synergies therefrom, (ix) the ongoing COVID-19 pandemic, * the timing and extent of governmental stimulus programs, and (xi) the uncertainty in the application of federal, state and local laws to our business, and any changes in such laws. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise except as required by law.

View original content to download multimedia:https://www.prnewswire.com/news-releases/schwazze-signs-definitive-documents-to-acquire-two-retail-dispensaries-from-smokeys-cannabis-company-301751397.html

SOURCE Schwazze

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is the purpose of Schwazze's acquisition of Smokey's dispensaries?

The acquisition aims to expand Schwazze's presence in northern Colorado's cannabis market.

What is the total value of Schwazze's acquisition announcement?

The acquisition is valued at US$7.5 million, comprising $3.75 million cash and $3.75 million stock.

How many dispensaries will Schwazze operate in Colorado after the acquisition?

With this acquisition, Schwazze will operate a total of 27 dispensaries in Colorado.

When is the acquisition of Smokey's dispensaries expected to close?

The acquisition is anticipated to close in the second quarter of 2023, subject to regulatory approvals.

What challenges could Schwazze face with the acquisition of Smokey's dispensaries?

Schwazze may face regulatory approval delays and potential dilution due to the stock component of the acquisition financing.